Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 3/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 5/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4074748 | 1.00 | P2RY6 (0.38) | P2RY6P2RY14TYMPNT5EDUT | |
| SCHEMBL7096692 | 0.89 | P2RY6 (0.41) | P2RY6P2RY14TYMPNT5EDUT | |
| SCHEMBL12386210 | 0.89 | P2RY6 (0.41) | P2RY6P2RY14TYMPNT5EDUT | |
| SCHEMBL4075035 | 0.89 | NT5E (0.40) | P2RY6P2RY14TYMPNT5EDUT | |
| SCHEMBL24512779 | 0.87 | TK2 (0.42) | — | |
| SCHEMBL5557408 | 0.87 | TK2 (0.42) | — | |
| SCHEMBL5582060 | 0.87 | TK2 (0.42) | — | |
| SCHEMBL2769235 | 0.87 | TK2 (0.42) | — | |
| SCHEMBL4074993 | 0.87 | DUT (0.34) | P2RY6P2RY14TYMPNT5EDUT | |
| SCHEMBL5878698 | 0.86 | SLC6A11 (0.39) | TYMPSLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1013661-B2 | 2'-O,4'-C-methylene bicyclonucleosides | EXIQON AS (DK) | 2018-10-24 | — | — | EP | disclosed |
| EP-2361921-B1 | Bicyclo-oligonucleotide analogues | EXIQON AS (DK) | 2015-06-03 | — | — | EP | disclosed |
| EP-2295441-B1 | Bicyclonucleoside Oligonucleotide Analogue | EXIQON AS (DK) | 2014-05-07 | — | — | EP | disclosed |
| US-RE44779-E1 | Bicyclonucleoside and oligonucleotide analogues | SANTARIS PHARMA A/S (DK) | 2014-02-25 | — | — | US | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| EP-1013661-B1 | 2'-O,4'-C-methylene bicyclonucleosides | EXIQON AS (DK) | 2012-01-18 | — | — | EP | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| EP-2361921-A2 | Novel bicyclonucleoside and oligonnucleotide analogue | Exiqon A/S (DK) | 2011-08-31 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| US-7569686-B1 | Compounds and methods for synthesis of bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-6268490-B1 | NUCLEOSIDE ANALOG; FOR ANTISENSE AGENT WHICH IS HYDROLASE RESISTANT, HAS HIGH SENSE STRAND BINDING ABILITY AND IS EASILY SYNTHESIZED | TAKESHI IMANISHI (JP) | 2001-07-31 | — | — | US | disclosed |
| EP-1013661-A1 | NOVEL BICYCLONUCLEOSIDE AND OLIGONUCLEOTIDE ANALOGUES | Imanishi, Takeshi (JP) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | P2RY6 2779/4885P2RY14 1842/4885TYMP 23/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | P2RY6 1694/4885P2RY14 1103/4885TYMP 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.